Omeros (NASDAQ:OMER) Coverage Initiated by Analysts at Rodman & Renshaw

Rodman & Renshaw began coverage on shares of Omeros (NASDAQ:OMER) in a research note released on Thursday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $9.00 target price on the biopharmaceutical company’s stock.

Separately, StockNews.com cut Omeros from a “hold” rating to a “sell” rating in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, two have given a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Omeros presently has an average rating of “Hold” and a consensus price target of $9.00.

Omeros Price Performance

Shares of NASDAQ:OMER traded down $0.20 during trading on Thursday, hitting $6.75. 1,931,790 shares of the company’s stock were exchanged, compared to its average volume of 466,108. The business’s 50-day simple moving average is $4.08 and its 200 day simple moving average is $4.07. Omeros has a 52-week low of $1.38 and a 52-week high of $7.51. The company has a market cap of $391.14 million, a price-to-earnings ratio of -2.89 and a beta of 1.47.

Hedge Funds Weigh In On Omeros

Several institutional investors and hedge funds have recently modified their holdings of the business. State Street Corp grew its stake in Omeros by 0.3% in the 3rd quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company’s stock valued at $4,867,000 after buying an additional 3,839 shares in the last quarter. HighTower Advisors LLC boosted its stake in Omeros by 7.2% during the third quarter. HighTower Advisors LLC now owns 59,339 shares of the biopharmaceutical company’s stock worth $235,000 after buying an additional 4,000 shares during the period. BNP Paribas Financial Markets increased its stake in shares of Omeros by 130.6% during the third quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 7,016 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of Omeros by 4.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 485,035 shares of the biopharmaceutical company’s stock valued at $1,926,000 after purchasing an additional 18,454 shares during the last quarter. Finally, SPC Financial Inc. acquired a new stake in Omeros during the third quarter valued at $77,000. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.